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Background: Left ventricular ejection fraction reserve (LVEFr = stress LVEF-rest LVEF) during dipyridamole Rubidium-82 (Rb-82) PET is inversely 
related to ischemic burden and a marker of multivessel coronary artery disease (CAD). We studied the relation between LVEFr with regadenoson (an 
agent with shorter duration of peak hyperemia) and the extent of ischemic burden on Rb-82 PET and angiographic CAD.
Methods: We included 398 patients (71 with invasive angiography within 180 days) who underwent regadenoson Rb-82 PET. Patients with atrial 
fibrillation, valvular heart disease, and coronary artery bypass were excluded. Patients received a fixed dose of 0.4 mg of regadenoson. The Rb-82 
images were interpreted semi quantitatively using a 17-segment model and a 0-4 scoring system to calculate summed stress, rest and difference 
(SDS) scores. Percentage of ischemic myocardium was estimated (SDS*100/68), and classified as no ischemia (0%), mild (1-5%), moderate (5-
10%) or severe ischemia (>10%). Angiographic CAD was defined as ≥50% for left main segment and ≥70% for other vessels. Differences in LVEFr 
were assessed by paired t-tests.
Results: The mean patient age was 63±12 years (63% women) with mean body mass index 34±9 kg/m2, and high frequency of hypertension 
(84%) and diabetes (35%). Among the patients with severe ischemia, LVEFr was 0.8±5%, significantly lower than patients with no (5.9±5%, 
P<0.0001), mild (4.3±7%, P=0.002) and moderate ischemia (5.3±5%, P<0.0001). The extent of CAD was determined by coronary angiography 
(median 3 days after PET) as no CAD (N=24), one vessel CAD (N=20), and multivessel CAD (≥2 vessel disease or left main disease, N=27). Among 
the patients with multivessel CAD, LVEFr was 1.6±5%, significantly lower than patients with no CAD (6.5±4%, P=0.002) and one vessel CAD (3±5%, 
P=0.002).
Conclusions: Inadequate LVEFr with regadenoson is associated with severe ischemia and may serve as a marker of increased CAD burden. LVEFr 
during regadenoson Rb-82 PET may have similar clinical implications as with dipyridamole stress.
